CollPlant Biotechnologies Ltd Ordinary Shares New CLGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT
-
LightSolver Files U.S. Provisional Patent Application Expanding its Photonic Computing Platform to Advanced Scientific and Engineering Simulations
-
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads
-
CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
CollPlant to Host LightSolver Investor Webinar on September 17, 2026
-
COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
-
COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR
Trading Information
- Previous Close Price
- $3.62
- Day Range
- $3.52–3.72
- 52-Week Range
- $2.64–23.80
- Bid/Ask
- $2.98 / $4.50
- Shares Outstanding
- 1.89M
- Market Cap
- $6.94M
- Volume/Avg
- 10,935 / 351,100
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 39
- Website
- https://www.collplant.com
Valuation
|
Metric
|
CLGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.77 |
Price/Sales | 15.26 |
Price/Cash Flow | — |
Price/Earnings
CLGN
Financial Strength
|
Metric
|
CLGN
|
|---|---|
Quick Ratio | 1.19 |
Current Ratio | 1.57 |
Interest Coverage | — |
Quick Ratio
CLGN
Profitability
|
Metric
|
CLGN
|
|---|---|
Return on Assets (Normalized) | −123.36% |
Return on Equity (Normalized) | −202.67% |
Return on Invested Capital (Normalized) | −148.04% |
Return on Assets
CLGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?$^$L> | LOCK|>BB? | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|bk$btw | LOCK|W#^RN | $84B | |||
| Moderna Inc
MRNA
| LOCK|!<dV>&R | LOCK|w$ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|@Vzy!W# | LOCK|dp | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@CLz^$W | LOCK|RG | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|x!&&xx | LOCK|#?@>P | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^PP#J$w | LOCK|m^>h | $28B | |||
| Incyte Corp
INCY
| LOCK|#c?zKb | LOCK|$<! | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@$B>y<Q | LOCK|$< | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$JQrJmH | LOCK|dt@ | $14B |
United States